This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klebig, C. Articles by Petersen, I. Search for Related Content PubMed PubMed Citation Articles by Klebig, C. Articles by Petersen, I.

Characterization of -Aminobutyric Acid Type A Receptor–Associated Protein, a Novel Tumor Suppressor, Showing Reduced Expression in Breast Cancer

¹ Institute of Pathology, University Hospital Charité; ² Department of Tumour Genetics, Max Delbrueck Center for Molecular Medicine; and ³ atugen AG, Berlin, Germany

Requests for reprints: Iver Petersen, Institute of Pathology, Charité Medical School, Humboldt-University, D-10098 Berlin, Germany. Phone: 49-30-450536050; Fax: 49-30-450536110; E-mail: iver.petersen{at}charite.de.

Frequent allelic loss of the chromosomal region 17p13 in breast cancer has suggested that more tumor suppressor genes, besides p53, are located in this region. By doing suppression subtractive hybridization to detect differentially expressed genes between the breast cancer cell line CAL51 and a nontumorigenic microcell hybrid CAL/17-1, we identified the gene for the -aminobutyric acid type A (GABA_A) receptor associated protein (GABARAP), located on 17p13.1. GABARAP displayed high expression levels in the microcell hybrid CAL/17-1 but only weak expression in CAL51 and other breast cancer cell lines tested. Furthermore, we observed large vesicles in CAL/17-1 by immunofluorescence staining, whereas no signal could be detected in the tumor cell line. GABARAP mRNA expression and protein expression were significantly down-regulated in invasive ductal and invasive lobular carcinomas compared with normal breast tissue measured by semiquantitative reverse transcription–PCR and immunohistochemistry, respectively. We assessed that neither mutations in the coding region of the gene nor hypermethylation of CpG islands in the promoter region are responsible for loss of gene expression in CAL51; however, 5-aza-2'-deoxycytidine treatment was effective in gene up-regulation, suggesting a methylation-dependent upstream effect. Stable transfection of GABARAP into CAL51 resulted in an increase of gene expression and remarkably influenced the ability of colony formation in soft agar and the growth rate in vitro and, moreover, suppressed the tumorigenicity of the cells in nude mice. In summary, our data suggest that GABARAP acts via a vesicle transport mechanism as a tumor suppressor in breast cancer.

Key Words: breast cancer • -aminobutyric acid type A (GABA_A) receptor associated protein • tumor suppressor • vesicle associated transport

This article has been cited by other articles:

				S. C. Reining, S. M. Gisler, D. Fuster, O. W. Moe, G. A. O'Sullivan, H. Betz, J. Biber, H. Murer, and N. Hernando GABARAP deficiency modulates expression of NaPi-IIa in renal brush-border membranes Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1118 - F1128. [Abstract] [Full Text] [PDF]

				M. Affara, B. Dunmore, C. Savoie, S. Imoto, Y. Tamada, H. Araki, D. S. Charnock-Jones, S. Miyano, and C. Print Understanding endothelial cell apoptosis: what can the transcriptome, glycome and proteome reveal? Phil Trans R Soc B, August 29, 2007; 362(1484): 1469 - 1487. [Abstract] [Full Text] [PDF]

				B. A. Walker, P. E. Leone, M. W. Jenner, C. Li, D. Gonzalez, D. C. Johnson, F. M. Ross, F. E. Davies, and G. J. Morgan Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma Blood, September 1, 2006; 108(5): 1733 - 1743. [Abstract] [Full Text] [PDF]